Case Report

Repeated intravenous thrombolysis in early recurrent stroke secondary to carotid web: Case report☆

Siham Bouchal, PhD, a,b,*, Youssef Alaoui Lamrani, PhD c, Naima Chtao, PhD a,b, Mustafa Maaroufi, PhD a, Faouzi Belahsen, PhD a,b

a Department of Neurology, Hassan II University Teaching Hospital, Sidi Harazem Road, PO Box 1835, Fez, 30070 Morocco
b Laboratory of Epidemiology, Clinical Research, and Health Community, Faculty of Medicine and Pharmacy, Sidi Mohammed Ben Abdallah University, Fez, Morocco
c Department of Radiology, Hassan II University Teaching Hospital, Fez, Morocco

A R T I C L E   I N F O

Article history:
Received 18 December 2020
Revised 6 January 2021
Accepted 11 January 2021

Keywords:
Previous stroke within 3 months
Recurrent intravenous thrombolysis
Early recurrent stroke
Carotid web artery
Symptomatic intracranial hemorrhage

A B S T R A C T

Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the first effective approved treatment for reducing ischemic stroke disability, and having a stroke within 3 months is usually a contraindication to thrombolysis. In this paper, we describe the case of a 58-year-old patient who received repeated intravenous thrombolysis at 10 days interval for a recurrent ischemic stroke, with dramatic improvement. The carotid diaphragm was behind this recurrent stroke and it was treated by stenting.

© 2021 Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

For a long time, history of stroke within 90 days had been considered an absolute contraindication to intravenous thrombolysis (IVT). However, some observational studies have shown the efficiency and safety of repeated thrombolysis in patients with early recurrent ischemic strokes.

Case report

A 58-year-old man with active smoking history presented with sudden-onset left-sided weakness, numbness, and speech difficulty for 90 minutes from his last known well. Neurological examination revealed a left central facial paralysis and left hemiplegia with dysarthria. The patient’s NIHSS was 13,
capillary glycaemia was normal, and blood pressure was 120/65 mm Hg. A cerebral computed tomography (CT) scan revealed attenuation (hypodensity) in the right insula and temporal lobe, indicating possible right middle cerebral artery (MCA) territory infarction with the Alberta Stroke Program Early CT score (ASPECTS) at 8. The CT angiography scan revealed an occlusion of the distal segment of M1 in the right middle cerebral artery (Figs. 1A and B). The intravenous tissue plasminogen activator Alteplase (0.9 mg/kg) was administered at 2 hours 15 minutes onset. The patient improved and his NIHSS was 3, five hours after thrombolysis.

Follow-up cerebral CT scan 24 hours later revealed the hypodense lesion compatible with partial right MCA infarction without any hemorrhagic transformation (Fig. 1C).

The CT angiography of the neck shows a small atheromatous plaque in the left common carotid artery without stenosis, and no abnormalities was observed in the right internal carotid artery at this time. Electrocardiogram, transthoracic echocardiography, and 24-hour Holter ECG were normal. The patient was discharged after four days, and was on daily antiplatelet agent (160 mg of aspirin) and statin (20 mg of atorvastatin).

Ten days after the first stroke, he was readmitted to the emergency department for the same non-epileptic neurological deficit after 1 hour from his last known well. The patient’s NIHSS was 14, and a CT scan of the brain showed the first infarction with distal vessel M1 thrombus in the right MCA (Figs. 2A and B). Since thrombectomy was not available, thrombolysis was discussed, and a full dose of IV-tPA was administered repeatedly. Dramatic improvement was observed and his NIHSS score was 4 at 10 hours after IVT. The CT angiography of the neck shows the right internal carotid artery web, not diagnosed after first stroke (Fig. 2C).

A control cerebral CT, performed 1 day after the second IVT, revealed the hypodense lesion compatible with the partial right MCA infarction, and an asymptomatic hemorrhagic transformation (Fig. 3).

The patient was stented 2 days after the last stroke with no periprocedural complications. The patient was discharged on daily dual antiplatelet agents (aspirin 100 mg and clopidogrel 75 mg) and atorvastatin (20 mg daily).

Three months later, the patient’s NIHSS score was 1, and his Modified Rankin Score was 0. He could manage all activities of daily living without assistance.
Discussion

Stroke is one of the most common health problems in the world, the third leading cause of death, and among the main causes of disability in the world, because of their frequency and severity. Ischemic stroke represents about 80% of all strokes [1]. Restoring blood flow, IVT with Alteplase was the first therapy to change the prognosis of ischemic stroke. Unfortunately, the percentage of patients who can benefit from this treatment is very low because it has numerous exclusion criteria. Nonetheless, in the real-world clinical practice, many stroke neurologists consider some of these contraindications to be “relative” and many patients receive off-label thrombolysis [2,3].

Most recently, thrombectomy has become the second method of reperfusion strategy to be approved [1]. Endovascular thrombectomy is the solution in situations where the use of intravenous alteplase is contraindicated, or insufficient. However, thrombectomy is not available in all emergency departments.

According to the European license, having a previous stroke within 3 months is one of exclusion criteria of IVT, because of the presumed higher risk of symptomatic intracranial hemorrhage (sICH). Some reviews and observational studies have re-examined this contraindication and concluded that IVT seems to be effective, and not as dangerous as previously believed [4].

The analysis of Stroke International Registry of Thrombolysis in Stroke (SITS) data between 2003 and 2010, indicates 1919 off-label thrombolysis. Around 2.7% of these violation criteria were previous stroke in the last 3 months [5]. According to the data of this multinational study, there is no evidence that a previous stroke within 3 months significantly increases the risk of sICH [5].

Recent reviews criticize the exclusion of patients with previous stroke within 3 months, and they have shown the effectiveness and the safety of thrombolysis in patients with early recurrent ischemic stroke, especially patients with the small infarction [4,6]. IVT for stroke recurring within 2 days from the previous event was described [4,7,8]. Adverse outcomes of repeated IVT are unknown, but theoretically, the rt-PA is cleared rapidly from the circulating blood and will not lead to toxic plasma levels. Repeated IVT twice and 3 times is performed in some cases with good outcomes [8,9].

It is necessary to discuss these exclusion criteria because the risk of early stroke recurrence is common [10]. Stroke recurrence has been associated with increased mortality and disability [10,11].

Identifying the cause of acute ischemic stroke is important to choose the appropriate secondary prevention of recurrence [12]. The Carotid web is an under-recognized cause for ischemic stroke, particularly in younger patients with no typical risk factors [12]. Its prevalence is between 10% and 37% in patients under 60 years of age with cryptogenic stroke [13]. It is associated with high risk of ischemic stroke recurrence, as demonstrated in our case, and in many other publications [13]. Antiplatelet monotherapy may be insufficient to prevent the recurrence of stroke secondary to carotid web. Endovascular therapy by stenting is potentially effective and technically safe [13].

Conclusion

Repeating IVT in early recurrence of stroke is safe, and potentially beneficial. History of previous stroke in the last 3 months, especially if thrombectomy is not available, should not be considered an absolute contraindication for IVT. Decision-making should take into consideration the supposed benefit and the potential risk.

Large clinical trials are needed to define the safe period for IV thrombolysis in early recurrent stroke, and to determine the appropriate dosage for repeated intravenous thrombolysis.

Ethics declarations

Ethics approval and consent to participate
The ethics committee of the UNIVERSITY HOSPITAL CENTRE HASSAN II FEZ MOROCCO has approved this report.

Consent for publication

Written informed consent was obtained from the patient’s legal guardian(s). A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Availability of data and materials

All data generated or analyzed during this study are included in this article.
REFERENCES

[1] Campbell BC. Thrombolysis and thrombectomy for acute ischemic stroke: strengths and synergies. SeminThrombHemost 2017;43(2):185–90 Epub 2016 Jul 29. PMID: 27472425. doi: 10.1055/s-0036-1585078.

[2] Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2016;47(2):581–641 Epub 2015 Dec 22. Erratum in: Stroke. 2016 Nov;47(11):e262. PMID: 26696642. doi: 10.1161/STR.0000000000000086.

[3] Fugate JE, Rabinstein AA. Absolute and relative contraindications to IV rt-PA for acute ischemic stroke. Neurohospitalist 2015;5(3):110–21. doi:10.1177/1941874415578532.

[4] Wu C, Wu D, Chen J, Li C, Ji X. Why not intravenous thrombolysis in patients with recurrent stroke within 3 months? Aging Dis 2018;9(2):309–16 Published 2018 Apr 1. doi:10.14336/AD.2017.0406.

[5] Karlinski M, Kobayashi A, Mikulik R, Sanak D, Wahlgren N, Czlonkowska A, et al. Intravenous alteplase in ischemic stroke patients not fully adhering to the current drug license in Central and Eastern Europe. Int J Stroke 2012;7(8):615–22 Epub 2012 Feb 7. PMID: 22309238. doi:10.1111/j.1747-4949.2011.00733.x.

[6] Sarmiento RJ, Diestro JDB, Espiritu AI, San Jose MCZ. Safety and efficacy of repeated thrombolysis with alteplase in early recurrent ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 2019;28(10):104290 Epub 2019 Jul 29. PMID: 31371140. doi:10.1016/j.jstrokecerebrovasdis.2019.07.006.

[7] Cappellari M, Moretto G, Bovi P. Repeated intravenous thrombolysis after recurrent stroke. A case series and review of the literature. J Neurol Sci 2014;345(1-2):181–3 Epub 2014 Jul 23. PMID: 25103750. doi: 10.1016/j.jns.2014.07.039.

[8] Brigo F, Bovi T, Tomelleri G, Bovi P, Moretto G. Repeated systemic thrombolysis after early recurrent stroke: always hazardous? Can J Neurol Sci 2012;39(1):114–16 PMID: 22384509. doi:10.1017/s0317167100022137.

[9] Nicolli F, Faiivre A, Squarcioni C, Combaz X, Girard N. Repeated MR-based intravenous thrombolysis in a patient with short interval stroke recurrences. J Neuroradiol 2011;38(4):256–8 Epub 2010 Nov 19. PMID: 21093916. doi:10.1016/j.neurad.2010.09.003.

[10] Arsava EM, Kim OM, Oliveira-Filho J, Gungor L, Noh HJ, LordeloMde J, et al. Prediction of early recurrence after acute ischemic stroke. JAMA Neurol 2016;73(4):396–401 PMID: 26926383. doi:10.1001/jamaneurol.2015.4949.

[11] Khanevski AN, Bjerkreim AT, Novotny V, et al. Recurrent ischemic stroke: incidence, predictors, and impact on mortality. ActaNeurol Scand 2019;140(1):3–8. doi:10.1111/anet.13093.

[12] Coutinho JM, Derkatch S, Potvin AR, et al. Carotid artery web and ischemic stroke: a case-control study [published correction appears in Neurology. 2017 Aug 1;89(5):521]. Neurology 2017;88(1):65–9. doi:10.1212/WNL.0000000000003464.

[13] Haussen DC, Grossberg JA, Bouslama M, Pradilla G, Belagaje S, Bianchi N, et al. Carotid web (Intimal Fibromuscular Dysplasia) has high stroke recurrence risk and is amenable to stenting. Stroke 2017;48(11):3134–7 Epub 2017 Oct 10. PMID: 29018133. doi:10.1161/STROKEAHA.117.019020.